Giampiero Porzio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7121670/publications.pdf

Version: 2024-02-01

103 papers 3,107 citations

32 h-index 205818 48 g-index

104 all docs

104 docs citations

104 times ranked 3414 citing authors

#	Article	IF	CITATIONS
1	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. Cancer Immunology, Immunotherapy, 2022, 71, 865-874.	2.0	11
2	High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. Journal of Hematology and Oncology, 2022, 15, 9.	6.9	5
3	Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. European Journal of Cancer, 2021, 142, 18-28.	1.3	81
4	Into the storms: Organising oncological home care services during natural disasters and global pandemics. European Journal of Cancer Care, 2021, 30, e13433.	0.7	1
5	Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care: a national survey. Supportive Care in Cancer, 2021, 29, 7845-7854.	1.0	7
6	Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Lifeâ€, Case-Control Study. Clinical Colorectal Cancer, 2021, , .	1.0	8
7	Clinical and psychometric validation of the BreSAS questionnaire module for symptom assessment among breast cancer survivors. Supportive Care in Cancer, 2020, 28, 1051-1058.	1.0	O
8	The PERSONS score: A new tool for cancer patients' symptom assessment in simultaneous care and home care settings. Palliative and Supportive Care, 2020, 18, 33-38.	0.6	4
9	Multimodality Treatment in Metastatic Gastric Cancer: From Past to Next Future. Cancers, 2020, 12, 2598.	1.7	11
10	Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice., 2020, 8, e001361.		126
11	Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE―Study. Cancers, 2020, 12, 1259.	1.7	19
12	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 ExpressionÂ≥ 50% and Their Relationship With Clinical Outcomes. Clinical Lung Cancer, 2020, 21, 498-508.e2.	1.1	50
13	Haloperidol for the treatment of opioid addiction in advanced cancer patients: a case series. Journal of Addictive Diseases, 2020, 38, 229-234.	0.8	4
14	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. European Journal of Cancer, 2020, 128, 17-26.	1.3	85
15	Family History of Cancer as Potential Prognostic Factor in Stage III Colorectal Cancer: a Retrospective Monoinstitutional Study. Journal of Gastrointestinal Cancer, 2020, 51, 1094-1101.	0.6	2
16	Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study. Scientific Reports, 2020, 10, 1456.	1.6	64
17	Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. Oncolmmunology, 2020, 9, 1710389.	2.1	9
18	Home Care for Cancer Patients During COVID-19 Pandemic: The Double Triage Protocol. Journal of Pain and Symptom Management, 2020, 60, e5-e7.	0.6	45

#	Article	IF	Citations
19	Careful Breakthrough Cancer Pain Treatment through Rapid-Onset Transmucosal Fentanyl Improves the Quality of Life in Cancer Patients: Results from the BEST Multicenter Study. Journal of Clinical Medicine, 2020, 9, 1003.	1.0	27
20	The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study. Palliative and Supportive Care, 2019, 17, 82-86.	0.6	4
21	Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2365-2373.	1.2	9
22	Cancer Care After Natural Disaster: Different Countries, Similar Problems. Journal of Global Oncology, 2019, 5, 1-2.	0.5	7
23	What cancer patients actually know regarding medical cannabis? A cross-sectional survey with a critical analysis of the current attitudes. Journal of Oncology Pharmacy Practice, 2019, 25, 1439-1444.	0.5	9
24	Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. Oncologist, 2019, 24, e327-e337.	1.9	131
25	A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. , 2019, 7, 57.		275
26	Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. Clinical Lung Cancer, 2019, 20, 237-247.e1.	1.1	118
27	Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice. Journal of Translational Medicine, 2019, 17, 376.	1.8	20
28	Predictive value of skeletal muscle mass for immunotherapy with nivolumab in nonâ€small cell lung cancer patients: A "hypothesisâ€generator―preliminary report. Thoracic Cancer, 2019, 10, 347-351.	0.8	54
29	The Incidence of Alcoholism in Patients with Advanced Cancer Receiving Active Treatment in Two Tertiary Care Centers in Italy. Alcohol and Alcoholism, 2019, 54, 47-50.	0.9	4
30	Where are we with treatment options after first line in small cell lung cancer?°â,,¢report of two opposite cases treated with CAPTEM regimen and possible perspectives. Journal of Thoracic Disease, 2018, 10, E520-E525.	0.6	0
31	Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab. Journal of Clinical Neuromuscular Disease, 2018, 20, 99-100.	0.3	2
32	Singleâ€institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in nonâ€small cell lung cancer patients treated with firstâ€line chemotherapy. Thoracic Cancer, 2018, 9, 1623-1630.	0.8	38
33	"Palliative―or "Supportive― Is It Just a Matter of Word?. Journal of Palliative Medicine, 2018, 21, 1546-1546.	0.6	0
34	Timed‑flat infusion of 5‑fluorouracil with docetaxel and oxaliplatin as first‑line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen. Oncology Reports, 2018, 40, 803-812.	1,2	3
35	Re. "Awareness and consideration of malnutrition among oncologists: Insights from an exploratory survey― Nutrition, 2017, 39-40, 96-97.	1.1	1
36	Knowledge and Attitudes of Young Italian Medical Oncologists Toward the Approach and Treatment of Pain: No Changes, Despite the Law. Pain Medicine, 2017, 18, 1822-1824.	0.9	3

#	Article	IF	CITATIONS
37	Caring for Cancer Patients After the Italian Earthquakes: A Proposal From the Field. Disaster Medicine and Public Health Preparedness, 2017, 11, 4-6.	0.7	1
38	Integration between Oncology and Palliative Care: A Plan for the Next Decade?. Tumori, 2017, 103, e23-e23.	0.6	0
39	Topical menthol for treatment of chemotherapy-induced peripheral neuropathy. Indian Journal of Palliative Care, 2017, 23, 350.	1.0	10
40	Pattern of symptoms and symptomatic treatment in adults and the aged population: a retrospective analysis of advanced cancer patients followed at home. Current Medical Research and Opinion, 2016, 32, 893-898.	0.9	5
41	Immigrants Accessing End-of-Life Care in Italy: The Tuscany Tumor Association Experience. Journal of Pain and Symptom Management, 2016, 51, e7.	0.6	1
42	Age differences in the last week of life in advanced cancer patients followed at home. Supportive Care in Cancer, 2016, 24, 1889-1895.	1.0	9
43	Comment on †What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain: Expert Opinion†M. Drugs, 2016, 76, 1059-1061.	4.9	1
44	Epidemiology and Characteristics of Episodic Breathlessness in Advanced Cancer Patients: An Observational Study. Journal of Pain and Symptom Management, 2016, 51, 17-24.	0.6	33
45	Is it possible to teach pain therapy playing basketball?. Annals of Palliative Medicine, 2016, 5, 71-3.	0.5	0
46	Pain Intensity as Prognostic Factor in Cancer Pain Management. Pain Practice, 2015, 15, E1-8.	0.9	19
47	The Frequency of Alcoholism in Patients With Advanced Cancer Admitted to an Acute Palliative Care Unit and a Home Care Program. Journal of Pain and Symptom Management, 2015, 49, 254-257.	0.6	12
48	Pain Characteristics and Analgesic Treatment in an Aged Adult Population: A 4-Week Retrospective Analysis of Advanced Cancer Patients Followed at Home. Drugs and Aging, 2015, 32, 315-320.	1.3	12
49	Prevalence of oral mucositis, dry mouth, and dysphagia in advanced cancer patients. Supportive Care in Cancer, 2015, 23, 3249-3255.	1.0	103
50	Fentanyl Buccal Tablet vs. Oral Morphine in Doses Proportional toÂtheÂBasal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Randomized, Crossover, Comparison Study. Journal of Pain and Symptom Management, 2015, 50, 579-586.	0.6	40
51	Sleep Disturbances in Patients With Advanced Cancer in Different Palliative Care Settings. Journal of Pain and Symptom Management, 2015, 50, 786-792.	0.6	69
52	Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain. Current Medical Research and Opinion, 2014, 30, 2063-2068.	0.9	17
53	Rapid Resolution of Refractory Chemotherapy-Induced Oral Mucositis With Platelet Gel-Released Supernatant in a Pediatric Cancer Patient: A Case Report. Journal of Pain and Symptom Management, 2014, 48, e2-e4.	0.6	7
54	New Opioids. Journal of Clinical Oncology, 2014, 32, 1671-1676.	0.8	18

#	Article	IF	Citations
55	Palliative Sedation in Patients With Advanced Cancer Followed at Home: A Prospective Study. Journal of Pain and Symptom Management, 2014, 47, 860-866.	0.6	42
56	The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting. Supportive Care in Cancer, 2013, 21, 2335-2339.	1.0	26
57	Relationship between background cancer pain, breakthrough pain, and analgesic treatment: a preliminary study for a better interpretation of epidemiological and clinical studies. Current Medical Research and Opinion, 2013, 29, 667-671.	0.9	31
58	Orphan symptoms in advanced cancer patients followed at home. Supportive Care in Cancer, 2013, 21, 3525-3528.	1.0	17
59	Is there a role for neurologist in an oncological home care team?. Neurological Sciences, 2013, 34, 115-116.	0.9	0
60	Prognostic Factors of Survival in Patients With Advanced Cancer Admitted to Home Care. Journal of Pain and Symptom Management, 2013, 45, 56-62.	0.6	39
61	Opioid Switching in Patients With Advanced Cancer Followed at Home. A Retrospective Analysis. Journal of Pain and Symptom Management, 2013, 45, 298-304.	0.6	20
62	Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids. Current Medical Research and Opinion, 2013, 29, 661-666.	0.9	42
63	The Effects of Low Doses of Pregabalin on Morphine Analgesia in Advanced Cancer Patients. Clinical Journal of Pain, 2013, 29, 15-19.	0.8	19
64	Integrating Oncology and Palliative Home Care in Italy: The Experience of the "L'Aquila per la Vita― Home Care Unit. Tumori, 2013, 99, 225-228.	0.6	8
65	Integrating oncology and palliative home care in Italy: the experience of the "L'Aquila per la Vita" Home Care Unit. Tumori, 2013, 99, 225-8.	0.6	9
66	Tapentadol in cancer pain management: a prospective open-label study. Current Medical Research and Opinion, 2012, 28, 1775-1779.	0.9	57
67	Palliative Care in Advanced Cancer Patients: How and When? And Where?. Oncologist, 2012, 17, e10-e11.	1.9	2
68	Emergencies in Patients With Advanced Cancer Followed at Home. Journal of Pain and Symptom Management, 2012, 44, 295-300.	0.6	39
69	Triplet Chemotherapy in Patients With Metastatic Colorectal Cancer: Toward the Best Way to Safely Administer a Highly Active Regimen in Clinical Practice. Clinical Colorectal Cancer, 2012, 11, 229-237.	1.0	18
70	Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. Current Medical Research and Opinion, 2012, 28, 963-968.	0.9	52
71	Octreotide for malignant bowel obstruction: Twenty years after. Critical Reviews in Oncology/Hematology, 2012, 83, 388-392.	2.0	42
72	Spinal analgesia for advanced cancer patients: An update. Critical Reviews in Oncology/Hematology, 2012, 82, 227-232.	2.0	18

#	Article	IF	CITATIONS
73	Palliative Sedation in Advanced Cancer Patients Followed at Home: A Retrospective Analysis. Journal of Pain and Symptom Management, 2012, 43, 1126-1130.	0.6	33
74	Central Nervous System Tumors. , 2012, , 1-18.		1
7 5	Does pain intensity predict a poor opioid response in cancer patients?. European Journal of Cancer, 2011, 47, 713-717.	1.3	18
76	Palliative Sedation in Patients with Advanced Cancer Followed at Home: A Systematic Review. Journal of Pain and Symptom Management, 2011, 41, 754-760.	0.6	87
77	How Do Cancer Patients Receiving Palliative Care at Home Die? A Descriptive Study. Journal of Pain and Symptom Management, 2011, 42, 702-709.	0.6	37
78	Home Care for Cancer Patients After an Earthquake: The Experience of the "L'Aquila per la Vita―Home Care Unit. Journal of Pain and Symptom Management, 2011, 42, e1-e4.	0.6	14
79	Can malignant bowel obstruction in advanced cancer patients be treated at home?. Supportive Care in Cancer, 2011, 19, 431-433.	1.0	21
80	Gabapentin in the Treatment of Hiccups in Patients With Advanced Cancer. Clinical Neuropharmacology, 2010, 33, 179-180.	0.2	51
81	Efficacy and safety of deep, continuous palliative sedation at home: a retrospective, single-institution study. Supportive Care in Cancer, 2010, 18, 77-81.	1.0	42
82	Breakthrough Pain in Oncology: AÂLongitudinal Study. Journal of Pain and Symptom Management, 2010, 40, 183-190.	0.6	55
83	Tools for Identifying Cancer Pain of Predominantly Neuropathic Origin and Opioid Responsiveness in Cancer Patients. Journal of Pain, 2009, 10, 594-600.	0.7	65
84	The palliative prognostic score and survival in patients with advanced solid tumors receiving chemotherapy. Supportive Care in Cancer, 2008, 16, 359-370.	1.0	46
85	Sustainedâ€release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. European Journal of Pain, 2008, 12, 1040-1046.	1.4	117
86	Timed-Flat Infusion of 5-Fluorouracil Associated with Docetaxel as First-Line Treatment of Patients with Metastatic Breast Cancer. Breast Journal, 2008, 14, 116-117.	0.4	0
87	Morphine in the Treatment of Incident Pain Triggered by Vinorelbine Infusion. Journal of Pain and Symptom Management, 2008, 35, 238-239.	0.6	2
88	Inappropriate Doses of Chemotherapy in Italian Breast Cancer Patients Enrolled in Clinical Trials. Tumori, 2007, 93, 540-543.	0.6	1
89	Is There Still a Role for the Uniscale Assessment of Quality of Life?. Tumori, 2007, 93, 78-81.	0.6	8
90	Switching from Transdermal Drugs: An Observational "N of 1―Study of Fentanyl and Buprenorphine. Journal of Pain and Symptom Management, 2007, 34, 532-538.	0.6	33

#	Article	lF	CITATIONS
91	Effective Analgesic Score: A "Marker―of the Effects of Chemotherapy on Pain in Advanced Cancer Patients?. Journal of Pain and Symptom Management, 2007, 34, 339-342.	0.6	5
92	Gabapentin in the treatment of severe sweating experienced by advanced cancer patients. Supportive Care in Cancer, 2006, 14, 389-391.	1.0	11
93	Safety and Effectiveness of Intravenous Morphine for Episodic Breakthrough Pain in Patients Receiving Transdermal Buprenorphine. Journal of Pain and Symptom Management, 2006, 32, 175-179.	0.6	72
94	Efficacy of Pregabalin in the Management of Cetuximab-Related Itch. Journal of Pain and Symptom Management, 2006, 32, 397-398.	0.6	54
95	Topical Morphine in the Treatment of Painful Ulcers. Journal of Pain and Symptom Management, 2005, 30, 304-305.	0.6	15
96	Pain evaluation and management: a survey of Italian radiotherapists. Supportive Care in Cancer, 2005, 13, 215-218.	1.0	3
97	The Supportive Care Task Force at the University of L'Aquila: 2-years experience. Supportive Care in Cancer, 2005, 13, 351-355.	1.0	30
98	Assessment and treatment of symptoms among Italian medical oncologists. Supportive Care in Cancer, 2005, 13, 865-869.	1.0	8
99	Use of strong opioids in advanced cancer pain: a randomized trial. Journal of Pain and Symptom Management, 2004, 27, 409-416.	0.6	160
100	Pruritus in a patient with advanced cancer successfully treated with continuous infusion of granisetron. Supportive Care in Cancer, 2004, 12, 208-209.	1.0	6
101	Knowledge and attitudes of italian medical oncology residents toward the approach and treatment of pain. Journal of Pain and Symptom Management, 2003, 26, 590-592.	0.6	6
102	Hiccup in patients with advanced cancer successfully treated with gabapentin: report of three cases. New Zealand Medical Journal, 2003, 116, U605.	0.5	14
103	Acupuncture in the treatment of menopause-related symptoms in women taking tamoxifen. Tumori, 2002, 88, 128-30.	0.6	17